Core Viewpoint - 泰禾股份 (301665) has reported that its product 百施佳 has gained traction across key provinces in China, with sales exceeding expectations in both channel and user segments, indicating a potential new growth driver for the company [1] Group 1 - 百施佳 has established agency platform clients in all key provinces nationwide [1] - Sales performance for 百施佳 has surpassed expectations in both distribution channels and user engagement [1] - The product is anticipated to become a new performance growth point for 泰禾股份 [1]

Group 1 - The core product, Baisijia, is a proprietary product developed by the company, indicating a focus on innovation and product differentiation [2] - The gross margin of the new product, Cyproconazole, is expected to exceed the average gross margin of the company's existing products, suggesting potential for improved profitability [2]